AP2003002796A0 - Disease prevention by reactivation of the thymus - Google Patents

Disease prevention by reactivation of the thymus

Info

Publication number
AP2003002796A0
AP2003002796A0 APAP/P/2003/002796A AP2003002796A AP2003002796A0 AP 2003002796 A0 AP2003002796 A0 AP 2003002796A0 AP 2003002796 A AP2003002796 A AP 2003002796A AP 2003002796 A0 AP2003002796 A0 AP 2003002796A0
Authority
AP
ARIPO
Prior art keywords
cells
thymus
lhrh
gene
preferred
Prior art date
Application number
APAP/P/2003/002796A
Inventor
Richard Boyd
Original Assignee
Richard Boyd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR0745A external-priority patent/AUPR074500A0/en
Priority claimed from US09/755,965 external-priority patent/US20010046486A1/en
Priority claimed from US09/965,395 external-priority patent/US20020081276A1/en
Application filed by Richard Boyd filed Critical Richard Boyd
Publication of AP2003002796A0 publication Critical patent/AP2003002796A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

The present disclosure provides methods for gene therapy utilizing hematopoietic stem cells, lymphoid progenitor cells, and/or myeloid progenitor cells. The cells are genetically modified to provide a gene that is expressed in these cells and their progeny after differentiation. In a preferred embodiment the cells contain a gene or gene fragment that confers to the cells resistance to HIV infection and/or replication. The cells arc administered to a patient in conjunction with treatment to reactivate the ppatient's thymus. The cells may be autologous, syngeneic, allogencic or xenogeneic, as tolerance to foreign cells is created in the patient during reactivation of the thymus. In a preferred embodiment the bcmatopoietic stem cells are CD34+. The patient's thymus is reactivated by diruption of sex steroid mediated Signaling to the Thymus. In a preferred embodiment, this disruption is created by administration of LHRH agonists,LHRH antagonists, anti-LHRH receptor antibodies-anti-LHRH vaccines or combinations thereof.
APAP/P/2003/002796A 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus AP2003002796A0 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US79528600A 2000-10-13 2000-10-13
US79530200A 2000-10-13 2000-10-13
AUPR0745A AUPR074500A0 (en) 2000-10-13 2000-10-13 Treatment of t cell disorders
US75564601A 2001-01-05 2001-01-05
US75598301A 2001-01-05 2001-01-05
US09/755,965 US20010046486A1 (en) 2000-04-17 2001-01-05 Stimulation of thymus for vaccination development
US75891001A 2001-01-10 2001-01-10
US09/965,395 US20020081276A1 (en) 1999-04-15 2001-09-26 Disease prevention by reactivation of the thymus
PCT/IB2001/002745 WO2002030259A2 (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus

Publications (1)

Publication Number Publication Date
AP2003002796A0 true AP2003002796A0 (en) 2003-06-30

Family

ID=27570138

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2003/002796A AP2003002796A0 (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus

Country Status (9)

Country Link
EP (1) EP1363703A4 (en)
CN (1) CN100406025C (en)
AP (1) AP2003002796A0 (en)
AU (1) AU1632302A (en)
BR (1) BR0114642A (en)
CA (1) CA2462681A1 (en)
IL (1) IL155414A0 (en)
NZ (1) NZ525830A (en)
WO (1) WO2002030259A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518699A (en) * 2003-04-18 2007-07-12 ノーウッド・イミュノロジー・リミテッド Disease prevention and vaccination before thymus regeneration
EP2187934A1 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of fertirelin and delta-endorphin as therapeutic agents
ES2598005T3 (en) 2009-08-14 2017-01-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymus output and to treat lymphopenia
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049805A (en) * 1975-09-30 1977-09-20 Akzona Incorporated Steroidal erythropoietic agents and therapeutic compositions and methods
CN1058500C (en) * 1993-02-03 2000-11-15 施塞克龙药品公司 Thymosin alpha-1 derivatives
WO1994026285A1 (en) * 1993-05-17 1994-11-24 The General Hospital Corporation Xenograft thymus
AUPP971499A0 (en) * 1999-04-12 1999-05-06 Opentec Pty. Limited On-line electoral system
AUPP977899A0 (en) * 1999-04-15 1999-05-13 Monash University Improvement of t cell mediated immunity

Also Published As

Publication number Publication date
BR0114642A (en) 2004-01-20
EP1363703A2 (en) 2003-11-26
WO2002030259A2 (en) 2002-04-18
CN100406025C (en) 2008-07-30
CA2462681A1 (en) 2002-04-18
WO2002030259A9 (en) 2003-08-07
NZ525830A (en) 2005-07-29
WO2002030259A3 (en) 2002-07-04
CN1505537A (en) 2004-06-16
IL155414A0 (en) 2003-11-23
EP1363703A4 (en) 2006-06-07
AU1632302A (en) 2002-04-22

Similar Documents

Publication Publication Date Title
Han et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases
Anrather et al. Inflammation and stroke: an overview
AU2013358904B2 (en) Methods modulating immunoregulatory effect of stem cells
Herrera et al. Human liver stem cells improve liver injury in a model of fulminant liver failure
Bonsack et al. Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury
JP2004521877A5 (en)
US20210213067A1 (en) Methods for enhancing immunosuppression
JP2001518289A5 (en)
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
AP2003002796A0 (en) Disease prevention by reactivation of the thymus
HĂŠrodin et al. Which place for stem cell therapy in the treatment of acute radiation syndrome?
AP2003002800A0 (en) Hematopoietic stem cell gene therapy
JP2017500316A (en) Method for repairing tissue damage using a protease resistant mutant of stromal cell-derived factor-1
Sadeghi et al. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review
Tsai et al. Stem cell therapy in stroke
Boregowda et al. Reconciling the stem cell and paracrine paradigms of mesenchymal stem cell function
KR101705378B1 (en) Composition for Preventing or Treating Graft-Versus-Host Disease Comprising Mesenchymal Stem Cell and IL-21 inhibitor
Giri Optimizing Mesenchymal Stromal Cells Delivery: Present Status and New Frontiers in Regenerative Medicine
Park et al. Human umbilical cord blood stem cells rescue ischemic tissues
Pfeiffer ITP: AMG 531 Shows Good Activity in Boosting Platelet Production
Zhang et al. Stem Cell Therapy in Chronic Periodontitis: Host Limitations and Strategies
Li et al. Anti-inflammatory effect of dental pulp stem cells
WO2002030257A3 (en) Normalization of defective t cell responsiveness through manipulation of thymic regeneration
CN116391030A (en) Transformed immune cells inducing chemotaxis of heterogeneous immune cells
Carlson Mesenchymal stem cells modulate immune system in GvHD patients